231 related articles for article (PubMed ID: 33648805)
21. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
22. An Overview of Characteristics of Clinical Next-Generation Sequencing-Based Testing for Hematologic Malignancies.
Zhang BM; Keegan A; Li P; Lindeman NI; Nagarajan R; Routbort MJ; Vasalos P; Kim AS; Merker JD
Arch Pathol Lab Med; 2021 Sep; 145(9):1110-1116. PubMed ID: 33450747
[TBL] [Abstract][Full Text] [Related]
23. Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies.
Levy MA; Santos S; Kerkhof J; Stuart A; Aref-Eshghi E; Guo F; Hedley B; Wong H; Rauh M; Feilotter H; Berardi P; Semenuk L; Yang P; Knoll J; Ainsworth P; McLachlin CM; Chin-Yee I; Kovacs M; Deotare U; Lazo-Langner A; Hsia C; Keeney M; Xenocostas A; Howlett C; Lin H; Sadikovic B
Eur J Haematol; 2019 Sep; 103(3):178-189. PubMed ID: 31177553
[TBL] [Abstract][Full Text] [Related]
24. The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice.
Northrup V; Maybank A; Carson N; Rahmeh T
Am J Clin Pathol; 2020 Apr; 153(5):639-645. PubMed ID: 31875888
[TBL] [Abstract][Full Text] [Related]
25. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.
Kothari N; Schell MJ; Teer JK; Yeatman T; Shibata D; Kim R
J Clin Pathol; 2014 Sep; 67(9):764-7. PubMed ID: 25004944
[TBL] [Abstract][Full Text] [Related]
26. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era.
Montes-Moreno S; Routbort MJ; Lohman EJ; Barkoh BA; Kanagal-Shamanna R; Bueso-Ramos CE; Singh RR; Medeiros LJ; Luthra R; Patel KP
PLoS One; 2018; 13(9):e0204218. PubMed ID: 30222780
[TBL] [Abstract][Full Text] [Related]
27. Machine Learning Predictability of Clinical Next Generation Sequencing for Hematologic Malignancies to Guide High-Value Precision Medicine.
Kim GYE; Noshad M; Stehr H; Rojansky R; Gratzinger D; Oak J; Brar R; Iberri D; Kong C; Zehnder J; Chen JH
AMIA Annu Symp Proc; 2021; 2021():641-650. PubMed ID: 35308914
[TBL] [Abstract][Full Text] [Related]
28. Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?
Rodler S; Jung A; Greif PA; Rühlmann K; Apfelbeck M; Tamalunas A; Kretschmer A; Schulz GB; Szabados B; Stief C; Heinemann V; Westphalen CB; Casuscelli J
Eur J Cancer; 2021 Mar; 146():1-10. PubMed ID: 33535139
[TBL] [Abstract][Full Text] [Related]
29. Next-generation sequencing in the clinic: promises and challenges.
Xuan J; Yu Y; Qing T; Guo L; Shi L
Cancer Lett; 2013 Nov; 340(2):284-95. PubMed ID: 23174106
[TBL] [Abstract][Full Text] [Related]
30. Next-generation sequencing-based panel testing for myeloid neoplasms.
Kuo FC; Dong F
Curr Hematol Malig Rep; 2015 Jun; 10(2):104-11. PubMed ID: 25933675
[TBL] [Abstract][Full Text] [Related]
31. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan.
Shimazawa R; Ikeda M
Expert Rev Mol Diagn; 2020 Jun; 20(6):601-610. PubMed ID: 32064968
[TBL] [Abstract][Full Text] [Related]
32. Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology.
Roloff GW; Drazer MW; Godley LA
JCO Precis Oncol; 2021 Nov; 5():107-122. PubMed ID: 34994594
[TBL] [Abstract][Full Text] [Related]
33. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
Miyamoto K; Minami Y
Int J Clin Oncol; 2019 Aug; 24(8):893-898. PubMed ID: 31111287
[TBL] [Abstract][Full Text] [Related]
34. Advances in next-generation sequencing and emerging technologies for hematologic malignancies.
Kwon R; Yeung CCS
Haematologica; 2024 Feb; 109(2):379-387. PubMed ID: 37584286
[TBL] [Abstract][Full Text] [Related]
35. Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.
Sasaki Y; Tamura M; Koyama R; Nakagaki T; Adachi Y; Tokino T
World J Gastroenterol; 2016 Feb; 22(7):2284-93. PubMed ID: 26900290
[TBL] [Abstract][Full Text] [Related]
36. Current concepts and future directions for hemato-oncologic diagnostics.
Flach J; Shumilov E; Joncourt R; Porret N; Novak U; Pabst T; Bacher U
Crit Rev Oncol Hematol; 2020 Jul; 151():102977. PubMed ID: 32446181
[TBL] [Abstract][Full Text] [Related]
37. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
38. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.
De Luca F; Rotunno G; Salvianti F; Galardi F; Pestrin M; Gabellini S; Simi L; Mancini I; Vannucchi AM; Pazzagli M; Di Leo A; Pinzani P
Oncotarget; 2016 May; 7(18):26107-19. PubMed ID: 27034166
[TBL] [Abstract][Full Text] [Related]
39. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
Lih CJ; Takebe N
Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
[TBL] [Abstract][Full Text] [Related]
40. Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.
Maslah N; Verger E; Schlageter MH; Miclea JM; Kiladjian JJ; Giraudier S; Chomienne C; Cassinat B
Ann Hematol; 2019 Jan; 98(1):111-118. PubMed ID: 30259120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
